Detalhe da pesquisa
1.
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
N Engl J Med
; 389(4): 297-308, 2023 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37356066
2.
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.
Circulation
; 145(8): 575-585, 2022 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34903039
3.
Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo.
Kidney Int
; 103(4): 772-781, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36738891
4.
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis.
Cardiovasc Diabetol
; 22(1): 220, 2023 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37620807
5.
Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials.
Expert Opin Emerg Drugs
; 28(1): 1-15, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36896700
6.
The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes.
Diabetes Obes Metab
; 25(3): 639-648, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36342041
7.
Metabolic and physiological responses to graded exercise testing in individuals with type 1 diabetes using insulin pump therapy.
Diabetes Obes Metab
; 25(3): 878-888, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36482870
8.
Impact of severe hypoglycaemia requiring hospitalization on mortality in people with type 1 diabetes: A national retrospective observational cohort study.
Diabetes Obes Metab
; 25(8): 2243-2254, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37139857
9.
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
N Engl J Med
; 381(9): 841-851, 2019 08 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31185157
10.
Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population-based observational retrospective cohort study.
Diabet Med
; 39(3): e14697, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34558105
11.
Ageing well with diabetes: A workshop to co-design research recommendations for improving the diabetes care of older people.
Diabet Med
; 39(7): e14795, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35064591
12.
Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease.
Diabet Med
; 39(4): e14769, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35080257
13.
Association of British Clinical Diabetologists and Renal Association guidelines on the detection and management of diabetes post solid organ transplantation.
Diabet Med
; 38(6): e14523, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33434362
14.
Extent and prevalence of post-exercise and nocturnal hypoglycemia following peri-exercise bolus insulin adjustments in individuals with type 1 diabetes.
Nutr Metab Cardiovasc Dis
; 31(1): 227-236, 2021 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33012641
15.
Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.
Cardiovasc Diabetol
; 19(1): 156, 2020 09 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32998732
16.
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
Diabetes Obes Metab
; 22(3): 442-451, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31903692
17.
The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.
Diabetes Obes Metab
; 22(9): 1690-1695, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32372454
18.
Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial.
Diabetes Obes Metab
; 22(11): 2077-2088, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32618386
19.
Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials.
Diabetes Obes Metab
; 22(11): 2193-2198, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32643857
20.
Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trials.
Diabetes Obes Metab
; 22(3): 303-314, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31608552